clinical trial · NCT05725291

AMT-116 in Patients With Advanced Solid Tumors

Multitude therapeutics Inc →·phase1·recruiting·n = 80

Advanced Solid TumorAMT-116

brief summary

This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-116, in Patients with Advanced Solid Tumors

started

Jul 25, 2023

primary completion

Dec 30, 2026

completion

Dec 30, 2026

last updated

Aug 17, 2025

official title

First-in-Human, Phase 1 Study of AMT-116 in Patients With Advanced Solid Tumors

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol